We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Axcella Health Inc (AXLA) USD0.001

Sell:$1.96 Buy:$2.14 Change: $0.09 (4.43%)
Market closed |  Prices as at close on 1 July 2022 | Switch to live prices |
Change: $0.09 (4.43%)
Market closed |  Prices as at close on 1 July 2022 | Switch to live prices |
Change: $0.09 (4.43%)
Market closed |  Prices as at close on 1 July 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Axcella Health Inc. is a clinical-stage biotechnology company focused on a new approach to treat complex diseases using compositions of endogenous metabolic modulators (EMMs). The Company’s product candidates are comprised of multiple EMMs that are engineered in distinct combinations and ratios with the goal of simultaneously impacting multiple biological pathways. AXA1665 is being developed as a product candidate for the reduction in risk of overt hepatic encephalopathy (OHE) recurrence in adult patients with liver cirrhosis. Its AXA1125 AXA1125 is being developed as an oral product candidate for the treatment of non-alcoholic steatohepatitis (NASH). The Company’s pipeline includes lead therapeutic candidates for the treatment of NASH, for the treatment of long COVID (also known as Post COVID-19 Condition and Post-Acute Sequelae of COVID-19, or PASC) associated fatigue, and for the reduction in risk of recurrent OHE.

Contact details

840 Memorial Dr
United States
+1 (617) 8680949

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$111.46 million
Shares in issue:
52.58 million
United States
US dollar

Key personnel

  • David Epstein
    Chairman of the Board
  • William Hinshaw
    President, Chief Executive Officer, Director
  • Robert Crane
    Chief Financial Officer
  • Virginia Dean
    Chief Human Resource Officer, Senior Vice President
  • Shreeram Aradhye
    Executive Vice President, Chief Medical Officer
  • Paul Fehlner
    Senior Vice President, Chief Legal Officer and Corporate Secretary
  • Margaret Koziel
    Senior Vice President, Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.